1. Volume 91, Issue 4, Pages 937-947 (April 2017)
Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management 
Agnieszka Bierzynska, Hugh J. McCarthy, Katrina Soderquest, Ethan S. Sen, Elizabeth Colby, Wen Y. Ding, Marwa M. Nabhan, Larissa Kerecuk, Shivram Hegde, David Hughes, Stephen Marks, Sally Feather, Caroline Jones, Nicholas J.A. Webb, Milos Ognjanovic, Martin Christian, Rodney D. Gilbert, Manish D. Sinha, Graham M. Lord, Michael Simpson, Ania B. Koziell, Gavin I. Welsh, Moin A. Saleem 
Kidney International 
Volume 91, Issue 4, Pages (April 2017)
DOI: /j.kint
Copyright © 2016 International Society of Nephrology Terms and Conditions

2. Figure 1
Kaplan-Meier plot showing percentage of kidney survival in the genetic and genetic mutation negative group of patients. Demonstrating faster rate of progression to end-stage renal failure (ESRF) in genetic versus nongenetic cases. Log-rank (Mantel-Cox) test (P < ).
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

3. Figure 2
Breakdown of monogenic causes versus genetic testing negative patients, according to age of onset of disease.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions

4. Figure 3
A precision medicine–based guide to investigation of steroid resistant nephrotic syndrome. *Patients 36, 88, 122, 160, 164, and 187 are steroid sensitive (focal segmental glomerulosclerosis on biopsy) or unknown and thus are not included in the figure. ∗∗Age of onset of end-stage renal failure (ESRF) was not known for patients 62 and 179, thus n = 30 for CKD5 patients and n = 28 for mean age of onset of ESRF; mean age of onset of nephrotic syndrome and mean age of onset of ESRF were compared, and the only significant difference was noted for the mean time to ESRF between primary + presumed monogenic and primary + presumed nonmonogenic and/or unknown and secondary steroid resistant nephrotic syndrome, with P = (2-tailed unpaired t test). KDIGO, Kidney Disease Improving Global Outcomes Guidelines.
Kidney International  , DOI: ( /j.kint )
Copyright © 2016 International Society of Nephrology Terms and Conditions